Welcome to our dedicated page for Gritstone bio news (Ticker: GRTS), a resource for investors and traders seeking the latest updates and insights on Gritstone bio stock.
Gritstone bio, Inc. (Nasdaq: GRTS) is at the forefront of developing personalized cancer immunotherapies and next-generation vaccines for infectious diseases. Headquartered in Emeryville, California, with additional key functions in Cambridge, Massachusetts, Gritstone is a clinical-stage biotechnology company leveraging innovative vectors and payloads to train the immune system to combat critical disease targets. Founded in 2015 with a strong financial backing of $102 million in Series A financing, Gritstone brings together a distinguished team of scientific founders, an experienced management team, and a successful board of directors.
Gritstone's pipeline includes multiple product candidates targeting solid tumors and viral diseases. Their key programs include GRANITE, a personalized neoantigen vaccine program, and SLATE, an 'off-the-shelf' neoantigen vaccine program. Additionally, they are developing CORAL, a next-generation SARS-CoV-2 vaccine designed to drive both B cell and T cell immunity using self-amplifying mRNA (samRNA). Gritstone's collaboration with the National Cancer Institute (NCI) and other industry leaders underscores the pioneering vision and scientific rigor that guides their innovative approaches.
Recent clinical updates have highlighted promising preliminary Phase 2 data for GRANITE in metastatic colorectal cancer (MSS-CRC), showing a progression-free survival benefit. SLATE-KRAS, a variant of their 'off-the-shelf' neoantigen vaccine, has also demonstrated superior immunogenicity in Phase 2 studies. Additionally, their CORAL program continues to show robust and durable immune responses in diverse populations, including those living with HIV.
Gritstone's financial condition remains strong, bolstered by recent public offerings and continued support from prominent foundations and government agencies. Their latest corporate developments and financial results reflect a clear trajectory towards advancing their clinical programs and achieving regulatory milestones.
Gritstone bio, Inc. (Nasdaq: GRTS) has been certified as a Great Place to Work by the Great Place to Work Institute, based on anonymous employee surveys. This recognition highlights the positive culture and work environment at Gritstone, emphasizing employee trust and camaraderie. Co-founder Andrew Allen noted the commitment to employee growth and mission-driven work. Great Place to Work Certification is a globally recognized benchmark for workplace experience, assessing employee perceptions of trust and engagement in their roles.
Gritstone bio (GRTS) reported updated overall survival (OS) results from its Phase 1/2 study of GRANITE, an individualized vaccine-based immunotherapy, demonstrating that patients with metastatic microsatellite stable colorectal cancer (MSS-CRC) achieving a molecular response had a median OS exceeding 18 months. This contrasts sharply with the 7.8 months observed in non-responders. The company plans to advance GRANITE into first-line treatment, aiming for improved patient outcomes. A 'Trial in Progress' poster for the Phase 2/3 GRANITE-CRC-1L study will be presented at the ASCO Annual Meeting on June 4, 2022.
Gritstone bio (Nasdaq: GRTS), a clinical-stage biotech firm, announced that CEO Andrew Allen will join a fireside chat at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. This event will be virtual and in-person, with the chat available on demand starting May 24 at 7 a.m. ET on Gritstone's website. The archived replay will be accessible for 30 days following the event. Gritstone is focused on developing potent vaccines using innovative vectors to target viral diseases and solid tumors.
Gritstone bio, a clinical-stage biotechnology company, reported its first quarter 2022 financial results with cash and equivalents of $186.8 million, down from $223.5 million in Q4 2021. The company is advancing multiple vaccine programs, including GRANITE for metastatic colorectal cancer and the CORAL second-generation SARS-CoV-2 vaccine, with data from several trials expected in the second half of 2022. However, collaboration and license revenue significantly decreased to $4.7 million compared to $39.7 million in the same period last year.
Gritstone bio, Inc. (GRTS) reported its Q1 2022 financial results, with cash reserves at $186.8 million, down from $223.5 million at year-end 2021. R&D expenses increased to $28.2 million from $24.9 million year-over-year, driven by higher personnel and service costs. Collaboration revenue fell sharply to $4.7 million from $39.7 million in Q1 2021. The company is advancing multiple Phase 2 clinical trials for its cancer and viral disease vaccine programs, with key data expected in the coming months.
Gritstone bio (Nasdaq: GRTS) plans to release its financial results for Q1 2022 and provide updates on May 5, 2022. They are engaging shareholders by partnering with Say Technologies to allow question submissions, with selected inquiries answered by management on May 11, 2022. The company focuses on developing immunotherapies for cancer and infectious diseases using its Gritstone EDGE™ platform. Their lead programs include the cancer immunotherapy GRANITE and the COVID-19 vaccine CORAL, supported by collaborations with NIH and Gilead Sciences.
Gritstone bio, Inc. (Nasdaq: GRTS) announced the grant of nonqualified stock options to nine employees, allowing them to purchase a total of 42,550 shares at an exercise price of $3.17. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and serves as an inducement for new hires. The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly. Gritstone is focused on developing advanced immunotherapies for cancer and infectious diseases, utilizing proprietary AI technology.
Gritstone bio, Inc. (Nasdaq: GRTS) presented significant findings at the 2022 AACR Annual Meeting. The company showcased its optimized, KRAS-specific vaccine candidate, SLATE-KRAS, now in Phase 2 trials, highlighting its potential to enhance T-cell responses. Additionally, data from the GRANITE program indicated that circulating tumor DNA (ctDNA) could be a predictive biomarker for overall survival in metastatic colorectal cancer. Presentations emphasized the effectiveness of self-amplifying mRNA (samRNA) in improving immune responses at lower doses, reinforcing Gritstone's standing in neoantigen vaccine development.
Onxeo S.A. has appointed
Gritstone bio, Inc. (Nasdaq: GRTS) announced the grant of nonqualified stock options for 14,800 shares to five new employees, with an exercise price of $4.90, equal to the closing price on the grant date of March 17, 2022. These options vest over four years, starting with 25% after one year. This measure aligns with Nasdaq Listing Rule 5635(c)(4) as an inducement for new hires. Gritstone is focused on developing immunotherapies for cancer and infectious diseases using its AI-based platform and is also advancing clinical studies for its leading oncology and infectious disease programs.
FAQ
What is the current stock price of Gritstone bio (GRTS)?
What is the market cap of Gritstone bio (GRTS)?
What does Gritstone bio, Inc. specialize in?
Where is Gritstone bio, Inc. headquartered?
What are Gritstone's key product candidates?
What recent clinical updates has Gritstone reported?
Who are Gritstone bio's collaborators?
When was Gritstone bio founded, and how was it funded?
What makes Gritstone's vaccines unique?
How does Gritstone's financial condition look?
What is the significance of the CORAL program?
What is the future outlook for Gritstone bio?
